Zoetis’ second quarter saw revenue and adjusted earnings surpass Wall Street expectations, but the market responded ...

Shares of Zoetis have been roughly average performers over the past decade. The shares seem appealingly valued at recent ...

The reality is that people and animals will always need medicine, treatments, and other products to live long and comfortable ...

Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and ...

Animal health company Zoetis (NYSE:ZTS) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 4.2% ...

Meanwhile, the company has an impeccable dividend program. The company has increased its payouts by 502% over the past decade ...

In a report released today, David Westenberg from Piper Sandler maintained a Buy rating on Zoetis, with a price target of $215.00. The company’s shares closed last Friday at $147.35. Take advantage of ...

Zoetis Inc. Q2 2025 earnings highlight 8% organic revenue growth, raised guidance, and strong performance from Simparica and Key Dermatology franchises.

Zoetis beats Q2 estimates with strong pet product sales and raises full-year guidance despite livestock sales decline and Librela weakness.

Zoetis (ZTS) stock surges premarket as the company posts strong Q2 2025 results and raises full-year outlook. Read more here.

Shares of Zoetis Inc. ZTS rallied 1.78% to $152.44 Wednesday, on what proved to be an all-around great trading session for ...

Breed Explorer offers veterinarian-approved, science-backed insights to help current and prospective pet owners make informed ...